장내 미생물 시장 규모는 2024년 7억 7,087만 달러 이상이었고 2037년까지 75억 6,000만 달러를 넘어 예측 기간(2025~2037년) 동안 CAGR 19.2% 이상 성장할 것으로 예상됩니다. 2025년 장내 미생물 산업 규모는 10억 2천만 달러로 추산됩니다.
The growth of the market can be attributed to the increased focus on human immune system post COVID-19, as people with low immunity have been most affected by the pandemic. According to the World Health Organization (WHO), as of March 23, 2023, there have been 76,107,1826 confirmed cases of COVID-19 worldwide, with 6,879,677 deaths to date. In addition, the increasing role of gut microbiota in immunity, in addition to the increasing research on ways to improve gut flora, is expected to further drive the market growth.
In addition to this, factors believed to be driving the market growth of gut microbiome include surging investments and collaborations among key players to research and develop human microbiome therapies to the next level . For instance, a new Bar-Ilan University study suggests that gut microbiome may be able to detect gestational diabetes in the first trimester of pregnancy, months earlier than it is typically detected. Rising concerns over gestational diabetes mellitus (GDM) globally, which afflicts about 10% of pregnant women worldwide, are expected to drive market expansion over the forecast period.
Growth engine
Increasing prevalence of gastrointestinal (GI) disorders – The gut microbiota is a vast and complex collection of microorganisms that impact human health in many ways. They are essential in helping humans absorb nutrients. Hence, the increasing consumption of unhealthy foods is expected to increase the prevalence of GI disorders among the global population and the rising stress levels among the middle-aged population worldwide are expected to drive the market growth. In the U.S., the estimated prevalence of irritable bowel syndrome is between 11% and 14% and this percentage is expected to increase further in the coming years.
Increasing prevalence of type 1 and type 2 diabetes - Changes in gut microbiota composition are known to be associated with the presence of chronic low-grade inflammation, which is a hallmark of insulin resistance and type 2 diabetes. The increasing prevalence of type 2 diabetes worldwide is expected to drive the market growth during the forecast period. According to studies, more than 37 million Americans (almost 1 in 10) have diabetes, of which about 90-95% have type 2 diabetes.
– According to recent spending data, global healthcare expenditure has increased over the past two decades, doubling in real terms to reach ~9.8% of GDP (USD 8.5 trillion) in 2019, up from ~8.5% in 2000. The market is estimated to thrive during the forecast period, owing to rising concerns over low gut microbiome diversity in children and middle-aged population.
Prevalence Rising – Diarrhea is the second most common cause of death in children under five, killing nearly 500,000 children under five each year, according to a World Health Organization (WHO) report. Additionally, approximately 2 billion children worldwide suffer from diarrheal diseases each year.
Since the intestines contain both good and bad bacteria, the entry of harmful bacteria into the gastrointestinal tract results in infection. Therefore, the market is expected to grow at a significant rate due to increasing research and spending to control infections that cause food poisoning and other gastrointestinal diseases, causing diarrhea and vomiting in the population.
challenge
|
기준 연도 |
2024년 |
|
예측 연도 |
2025년부터 2037년까지 |
|
CAGR |
19.2% |
|
기준연도 시장 규모(2024년) |
7억 7,087만 달러 |
|
예측 연도 시장 규모(2037년) |
75억 6천만 달러 |
|
지역 범위 |
"
" |
The global gut microbiota market is segmented and analyzed based on demand and supply by application for therapeutics and diagnostics. Among the two types of gut microbiota, this segment is expected to account for the largest market share of ~60% in 2037. The growth of this segment can be attributed to the increasing spending on biomedical biopharmaceutical and biotechnology industries globally and the increase in biopharmaceutical sales post COVID-19. For instance, biopharmaceuticals accounted for ~40% of the total pharmaceutical sales worldwide in 2021. Additionally, in addition to the increasing technological advancements in the therapeutics segment, increasing R&D collaborations among key market players to better understand human gut health and develop distinct drug delivery systems to improve the balance of gut microbiota are expected to further drive the segment growth.
The global gut microbiota market is also segmented and analyzed by disease-wise demand and supply, including autoimmune diseases, gastrointestinal disorders, and infectious diseases. Among these three segments, the infectious segment is expected to hold a significant share of ~45% by 2037. The growth of this segment is supported by the increasing prevalence of unspecified gastroenteritis and the increasing number of patients suffering from diarrheal diseases, in addition to the rising cases of acute gastrointestinal (GI) infections due to Campylobacter, non-typhoidal Salmonella, Shigella, Escherichia coli (E. coli), or norovirus. For instance, as per the report, unspecified gastroenteritis/diarrhea accounted for more than 98% of the diagnosed cases in the US between 2010 and 2019. Additionally, around 2,241 cases of Campylobacter infections were diagnosed during the same period, followed by Salmonella infections, Shigella, Escherichia coli (E. coli), or norovirus.
The in-depth analysis of the global gut microbiota market includes the following segments:
|
By product |
|
|
By application |
|
|
By disease |
|
The European gut microbiome market is estimated to be the second largest market, accounting for ~25% share by the end of 2037. The growth of the market can be primarily attributed to the rapidly growing geriatric population, as well as the increasing prevalence of heart diseases and other chronic diseases, coupled with increasing research and development and clinical trials in the microbiome therapeutics sector in the region. It was found that by 2022, more than one-fifth or 21% of the population in the European Union will be aged 65 years or older. Additionally, increasing awareness about preventive healthcare in the region is expected to further propel the regional market growth.
Additionally, the Asia Pacific region is expected to hold the majority share among all other regional markets by the end of 2037. The presence of a large pooled population and the increasing prevalence of autoimmune diseases such as celiac disease, diabetes, asthma, and cancer are leading to an increase in the prevalence of obesity and other lifestyle-related diseases. For instance, a study conducted in 2019 on approximately 19,778 Chinese adolescents and young adults found that the prevalence of celiac disease autoimmune was nearly 2.19% in China. Furthermore, the prevalence of diabetes in Chinese adults is expected to increase from ~8% to nearly 9.5% in the age group of 20-79 years between 2020 and 2030.
저자 크레딧: Radhika Pawar
무료 샘플 사본에는 시장 개요, 성장 추세, 통계 차트 및 표, 예상 예측 등이 포함됩니다.
이 보고서를 주문하기 전에 질문이 있으십니까?